Market Overview

UPDATE: Deutsche Bank Raises PT on Allergan on Q4 EPS

Related AGN
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Benzinga's Top Downgrades
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

In a report published Wednesday, Deutsche Bank reiterated its Buy rating on Allergan (NYSE: AGN), and raised its price target from $108.00 to $113.00.

Deutsche Bank noted, “Q4 EPS $0.03 Better Including R&D Tax Credit. Allergan reported non-GAAP adjusted Q4 EPS of $1.15, excluding $0.06 from an R&D tax credit that was not signed into law until Jan 2013. Including this tax credit, which will now be booked in 1Q13, Q4 EPS would have been $1.21, or $0.03 ahead of consensus. Gross margin of 87.5% was 102 bp above our est while spending came in $17M above expectations. Post the solid Q4 results, we continue to rate the company's shares BUY, in part due to AGN's broad diversification across products and geographies, its mix of reimbursed vs cashpay businesses, and the sustainability of its revenue base.”

Allergan closed on Tuesday at $106.70.

Latest Ratings for AGN

DateFirmActionFromTo
Dec 2014Goldman SachsDowngradesBuyHold
Dec 2014Stifel NicolausDowngradesBuyHold
Dec 2014CitigroupMaintainsBuy

View More Analyst Ratings for AGN
View the Latest Analyst Ratings

Posted-In: Deutsche BankAnalyst Color Price Target Analyst Ratings

 

Related Articles (AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters